
Device Support Specialist, New Indications Germany - Thüringen area (W/M/D)
Field Based / Full Time / Permanent contract
At Novocure, every role contributes to extending the lives of people living with cancer. As our new Device Support Specialist New Indications in Germany (Thüringen area), you’ll play a key part in this mission.
The Device Support Specialist, New Indications is a key position within the Center of Excellence business unit, with a clinical trial patient focus. The primary role of this position is to support clinical trial oncology patients utilizing Tumor Treating Fields (TTFields) therapy in Germany.
This is an exempt, full-time, field-based position reporting to the Snr, New Indications DSS Lead, EMEA.
These additional qualifications are preferred:
Novocure is a company with a powerful mission, to extend the lives of people living with some of the most aggressive forms of cancer. Here your work will have a direct impact on patients and those who care about them. Join a team of passionate, collaborative people who support each other, challenge one another, and innovate together. Here, you’ll connect, grow, and make a real difference. We’re a company with the drive of a startup and the strength that comes with 25 years of success.
Novocure operates at a rare crossroad, where advanced medical technology converges with cutting-edge biotechnology. We are the only company to develop and commercialize Tumor Treating Fields (TTFields), a proprietary, groundbreaking therapy designed to disrupt cancer cell division. With us you will find a unique combination of laboratory research work alongside engineering development of advanced technologies. This fusion of disciplines positions us as true pioneers in oncology innovation, leading a new frontier in the treatment of aggressive cancers.
If you're excited about this role, please apply.

We are a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of our innovative therapy, Tumor Treating Fields. Our commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and in the U.S. for the treatment of adult patients with malignant pleural mesothelioma. We have ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and gastric cancer.
Headquartered in Switzerland, Novocure has U.S. operations in Portsmouth, New Hampshire and Chesterbrook, Pennsylvania. Additionally, Novocure has offices in Canada, Germany, Japan, Poland and Israel.